In both articles, Thy-1/CD90 acts as a β3 integrin ligand, however, in liver cancer cells, Thy-1/CD90 is presented as a carcinogenesis promoter, whereas in ovarian cancer, it is an inhibitor of cancer formation. Here, THY1 is linked to ovarian cancer.